Orum Therapeutics

Ascend to New Heights

Founded 2016 · $268.0M raised

Employees
51–200
Founded
2016
Business Model
B2B
Website
orumrx.com
Total Funding
$268.0M
Last Round
$100.0M Venture RoundDec 2025
Rounds
4

About

Orum Therapeutics is a public, clinical-stage biotechnology company developing degrader-antibody conjugates (DACs) through its proprietary TPD² platform, which combines catalytic targeted protein degradation with the tumor-targeting precision of therapeutic antibodies. Founded in 2016, the company is headquartered in Daejeon, South Korea, with a U.S. site in Lexington, Massachusetts. Its lead candidate, ORM-1153, is a CD123-targeting degrader-antibody conjugate in development for acute myeloid leukemia. In December 2025 Orum raised approximately $100 million (145 billion KRW) led by KB Investment, with participation from IMM Investment, Woori Venture Partners, Weiss Asset Management, and Korea Investment Partners.

Summary

Orum Therapeutics is a Biotech company, founded in 2016. It has raised $268.0M in total across 4 rounds, most recently a $100.0M Venture Round round in Dec 2025. Investors include KB Investment, IMM Investment and KIP Global Pharma Private Equity Fund.

Funding History

Venture RoundVenture RoundDec 2025
$100.0M

Sign up to see all 4 rounds

Series B through Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Orum Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/orum-therapeutics"><img src="https://indexed.vc/api/badge/company/orum-therapeutics" alt="Orum Therapeutics on Indexed.vc" width="260" height="76" /></a>